ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc Corporate Call Announces Top-line Results from Phase 3 ENHANCE Trial Transcript

Jul 22, 2019 / 09:00PM GMT
Release Date Price: $25.97 (+1.05%)
Operator

Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals conference call. My name is Carmen, and I'll be your coordinator for today. (Operator Instructions) I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.

Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

Thank you, Carmen. Good afternoon and thank you for joining us on today's call to discuss the top line results from the Phase III ENHANCE study evaluating pimavanserin as an adjunctive schizophrenic treatment for adult patients with inadequate response to their existing antipsychotic therapy.

On today's call Steve Davis, our Chief Executive Officer, will provide opening remarks. Following Steve, Dr. Serge Stankovic, our President, will discuss the Phase III ENHANCE results in greater details. Following Steve's closing remarks, we'll conduct a Q&A session. Michael Yang, our Chief Commercial Officer; and Elena Ridloff, our Chief Financial Officer, will also be available for Q&A. I would also like to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot